Global ASCVD Trends and Emerging Strategies

Current Status

Not Enrolled

Price

Free

Get Started

Start Course

Global ASCVD Trends and Emerging Strategies

SESSÃO DE ABERTURA: Manejo da Obesidade – A Perspectiva do Paciente e do Provedor

Introduction: Prof. Raul Santos

Video 1: Epidemiology and pathophysiology of obesity and CVD

Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?

Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease

Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD

Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient

Part 1: The History in the Battle of Insulin and Glucagon

Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?

Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares

Course Content

Video 1 – Evidence of LDL-C as a Cause of Atherosclerotic Cardiovascular Disease

Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide

Video 3 – For ASCVD Prevention the Lower the LDL-C the Better

Video 4 – Safety of Intensive LDL-C Reduction

Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins

Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness

Video 7 – Efficacy, Feasibility, and Safety of Early Use of Monoclonal PCSK9 Inhibitors after an Acute Coronary Syndrome

Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients

Video 9 – Future Therapies for Dyslipidemia Treatment

Global ASCVD Trends and Emerging Strategies Final Survey

Course Content

Video 1 – Evidence of LDL-C as a Cause of Atherosclerotic Cardiovascular Disease

Video 2 – The Sad and Inadequate Reality of Cholesterol Control Worldwide

Video 3 – For ASCVD Prevention the Lower the LDL-C the Better

Video 4 – Safety of Intensive LDL-C Reduction

Video 5 – Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoproteins

Video 6 – Impact of PCSK9 Inhibition in Very High-Risk Patients and How to Increase Cost Effectiveness

Video 7 – Efficacy, Feasibility, and Safety of Early Use of Monoclonal PCSK9 Inhibitors after an Acute Coronary Syndrome

Video 8 – Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients

Video 9 – Future Therapies for Dyslipidemia Treatment

Global ASCVD Trends and Emerging Strategies Final Survey

Global ASCVD Trends and Emerging Strategies

Vídeo 3: Farmacoterapias para obesidade e prevenção de DCV

Video 3: Pharmacotherapies for Obesity and CVD Prevention

Vídeo 2: Obesidade e Lesão em Órgãos-Alvo

Activity

Video 2: Obesity and Target Organ Damage

Activity

Activity

Vídeo 1: Epidemiologia da Obesidade e Doença Cardiovascular

Video 1: Epidemiology and Pathophysiology of Obesity and CVD

Introduction: Prof. Raul Santos

SESSÃO DE ABERTURA: Manejo da Obesidade – A Perspectiva do Paciente e do Provedor

Introduction: Prof. Raul Santos

Video 1: Epidemiology and pathophysiology of obesity and CVD

Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?

Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease

Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD

Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient

Part 1: The History in the Battle of Insulin and Glucagon

Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?

Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares

Course Content

Course Content